When designing a product, a manufacturer has a duty to exercise care in selecting from among alternative product designs to reduce the foreseeable risks of harm presented in the use of the product.
Background: Apixaban (2.5 mg) taken twice daily has been shown to substantially reduce the risk of venous thromboembolism (VTE) compared with placebo for the primary thromboprophylaxis of ambulatory ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback